
    
      This is a post-market, multi-center, prospective, open, randomized controlled clinical study.
      The total study duration for each patient should be 36 ± 2 months.

      Roxolid Standard Plus Implants, 4 mm, Ø 4.1 mm, SLActive will be placed in positions 36/46 or
      35/45, 36/46.

      Roxolid Standard Plus Implants, Ø 4.1 mm, SLActive, in lengths of 10, 12 and 14 mm will be
      placed in positions 33/43.

      In total 10 visits per patient are scheduled in this study. Implant survival, implant
      success, prosthetic survival and success, and adverse events (AEs) will be assessed.

      All products are CE-(Conformité Européenne, meaning European Conformity) marked and used
      within its intended use.

      Two centers in Switzerland and Northern Ireland will participate. The study and any
      amendments will be performed according to International Organization for Standardization
      (ISO) 14155:2011, local legal and regulatory requirements and conform to the Declaration of
      Helsinki (last revision Fortaleza 2013)
    
  